These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 18199104)

  • 1. Antiproteinuric and anti-inflammatory effects of thiazolidinedione.
    Szeto CC; Li PK
    Nephrology (Carlton); 2008 Feb; 13(1):53-7. PubMed ID: 18199104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptor gamma agonists in renal disease.
    Iglesias P; Díez JJ
    Eur J Endocrinol; 2006 May; 154(5):613-21. PubMed ID: 16645006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 2 diabetes, psoriasis and thiazolidinediones.
    Krentz AJ; Friedmann PS
    Int J Clin Pract; 2006 Mar; 60(3):362-3. PubMed ID: 16494655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy.
    Pistrosch F; Passauer J; Herbrig K; Schwanebeck U; Gross P; Bornstein SR
    Horm Metab Res; 2012 Nov; 44(12):914-8. PubMed ID: 22723267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
    Blaschke F; Caglayan E; Hsueh WA
    Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
    Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone loss and fracture risk associated with thiazolidinedione therapy.
    Riche DM; King ST
    Pharmacotherapy; 2010 Jul; 30(7):716-27. PubMed ID: 20575635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPAR-gamma-agonists' renal effects.
    Izzedine H; Launay-Vacher V; Buhaescu I; Heurtier A; Baumelou A; Deray G
    Minerva Urol Nefrol; 2005 Dec; 57(4):247-60. PubMed ID: 16247347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular effects of the thiazolidinediones.
    Qayyum R; Schulman P
    Diabetes Metab Res Rev; 2006; 22(2):88-97. PubMed ID: 16184618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiazolidinedione therapy is not associated with increased colonic neoplasia risk in patients with diabetes mellitus.
    Lewis JD; Capra AM; Achacoso NS; Ferrara A; Levin TR; Quesenberry CP; Habel LA
    Gastroenterology; 2008 Dec; 135(6):1914-23, 1923.e1. PubMed ID: 18930061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Heart failure with thiazolidinedione treatment: what do we know today?].
    Erdmann E
    Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor γ with Excellent Effect on Insulin Resistance and Type 2 Diabetes.
    Liu HJ; Zhang CY; Song F; Xiao T; Meng J; Zhang Q; Liang CL; Li S; Wang J; Zhang B; Liu YR; Sun T; Zhou HG
    J Pharmacol Exp Ther; 2015 Jun; 353(3):573-81. PubMed ID: 25876909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minireview: Challenges and opportunities in development of PPAR agonists.
    Wright MB; Bortolini M; Tadayyon M; Bopst M
    Mol Endocrinol; 2014 Nov; 28(11):1756-68. PubMed ID: 25148456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
    Consoli A; Formoso G
    Diabetes Obes Metab; 2013 Nov; 15(11):967-77. PubMed ID: 23522285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy?
    Zheng F; Guan Y
    Kidney Int; 2007 Dec; 72(11):1301-3. PubMed ID: 18004308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes.
    Setti G; Hayward A; Dessapt C; Barone F; Buckingham R; White K; Bilous R; Hiroshi K; Gruden G; Viberti G; Gnudi L
    Am J Nephrol; 2010; 32(5):393-402. PubMed ID: 20814199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.